ICER releases draft evidence report on ulcerative colitis therapies

26 May 2020 - Public comment period now open until 29 July 2020; requests to make oral comment during public meeting ...

Read more →

ISPOR holds its first completely virtual conference

21 May 2020 - Virtual ISPOR 2020 plenaries focused on health policy, big data and artificial intelligence, cost effectiveness analysis and ...

Read more →

Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work?

20 May 2020 - On April 29, the National Institutes of Health announced that in a placebo-controlled trial of patients with ...

Read more →

ICER posts draft scoping document for the assessment of supervised injection facilities

19 May 2020 - Document open to public comment until 9 June 2020. ...

Read more →

International reference pricing gets thumbs down from ISPOR panel

18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...

Read more →

Putting a dollar value on life? Governments already do

11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...

Read more →

ICER appoints new members to each of its three independent evidence appraisal councils

14 May 2020 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...

Read more →

ICER’s cost model is not only wrong it’s also dangerous

11 May 2020 - There they go again. ...

Read more →

How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?

 7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...

Read more →

ICER presents alternative pricing models for remdesivir as a treatment for COVID-19

1 May 2020 - Models present prices according to two different paradigms: “cost recovery” approach and traditional cost-effectiveness analysis. ...

Read more →

The global imperative to make cancer medications affordable

1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...

Read more →

Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?

30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...

Read more →

ICER releases evidence report on treatments for cystic fibrosis

27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...

Read more →

ICER Appoints Jon Campbell as Senior Vice President for Health Economics

23 April 2020 - In September, Jonathan D. Campbell, PhD, will become Senior Vice President for Health Economics at the Institute ...

Read more →

America can afford a world class health care system. Why don’t we have one?

14 April 2020 - In March, Congress passed a coronavirus bill including $3.1 billion to develop and produce drugs and ...

Read more →